PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients

Dec 02, 2009

Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death, according to a study in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

PSA levels in a prostate cancer patient are monitored after a patient's treatments, and after a successful course of EBRT the levels should decline gradually over the following 18 to 24 months. A continued rise in PSA can indicate relapsing disease.

Prior studies have attempted to categorize PSA response patterns after treatment in an effort to identify patients with an increased chance of a relapse earlier; however, most did not use a fixed point after treatment to predict outcomes.

Researchers at the Memorial Sloan-Kettering Cancer Center department of and Epidemiology and Biostatistics in New York, sought to determine the significance of a patient's reaching a certain at a specific point in time after EBRT.

The study authors found that patients with a PSA value of less than or equal to 1.5 at two years had a 2.4 percent incidence of distant metastases at five years after treatment and a 7.9 percent incidence at 10 years after treatment. Patients with a PSA value higher than 1.5 experienced a significantly higher rate of metastases at five and 10 years after treatment (10 percent and 17.5 percent, respectively).

"In the past, patients with a relapsing cancer after receiving radiation were not identified until several years after treatment and at that point it may be too late to effectively salvage their recurrence," Michael Zelefsky, M.D., lead author of the study and a radiation oncologist at Memorial Sloan-Kettering Cancer Center, said. "If we can catch these future instances of cancer recurrence earlier in patients, then we have a much higher chance of reducing the mortality associated with the ."

Source: American Society for Radiation Oncology

Explore further: Generation of tanners see spike in deadly melanoma

add to favorites email to friend print save as pdf

Related Stories

IGRT may improve outcomes for obese prostate cancer patients

Sep 02, 2009

Moderately to severely obese prostate cancer patients may have improved treatment outcomes when treated with image-guided radiation therapy (IGRT) over traditional external beam radiation therapy (EBRT) because IGRT corrects ...

Radiation therapy combo cures prostate cancer long-term

Jan 04, 2007

Seventy-four percent of men treated with a combination of radiation seed implants and external beam radiation therapy for prostate cancer are cured of their disease 15 years following their treatment, according to a study ...

Recommended for you

Generation of tanners see spike in deadly melanoma

2 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

3 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

15 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments : 0